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patients presented an overall clinical improvement of ≥ 20%, ≥ 50% and ≥ 80%. These 
improvements were associated with a reduction of steroid use (75% of patients 
on steroids at belimumab-initiation decreased mean dose from 14.8 to 6.8mg/day; 
p< 0.001) and HRU between the pre/post index periods: emergency-room visits 1.65 
to 0.41; p= 0.001; unscheduled visits to treating-physician 1.02 to 0.03; p< 0.001, 
visits to other specialists (1.64 to 1.06; p= 0.017) and antibody tests (7.78 to 7.53; 
p= 0.47). An increase in HRU was observed for hematological and renal tests (3.14 to 
3.52; p= 0.045) and (5.95 to 6.59; p= 0.024), respectively. Working patients (39%) also 
showed a reduction in the LA days between the pre/post index periods (25.6 to 5.7 
days; p= 0.025). ConClusions: Belimumab treatment yielded improved clinical 
outcomes and a reduction in HRU directly related with SLE management, as corti-
coid use. Mean number of LA days also showed a substantial reduction, especially 
important in SLE, mostly affecting young patients.
SYSTEMIC DISORDERS/CONDITIONS – Patient-Reported Outcomes & Patient 
Preference Studies
PSY74
IMPaCT Of PaTIENT PROgRaMS ON aDhERENCE IN INflaMMaTION aND 
IMMuNOlOgY: a glObal SYSTEMaTIC REvIEw aND METa-aNalYSIS Of 
PublIShED EvIDENCE
Burudpakdee C.1, Khan Z.M.2, Gala S.1, Nanavaty M.1, Kaura S.2
1MKTXS, Raritan, NJ, USA, 2Celgene Corporation, Summit, NJ, USA
objeCtives: Patient adherence is important for successful treatment in chronic 
conditions, including inflammation and immunology (I&I) diseases, to improve 
patient outcomes. Programs and interventions that aim at improving medica-
tion adherence play an essential role in optimizing care. This review and meta-
analysis assessed the effectiveness of different types of adherence programs in 
I&I. Methods: A global systematic literature search was conducted and studies 
were identified from PubMed, conference proceedings, and grey literature. Selection 
criteria included studies of patient programs in I&I diseases published in English 
language between January 2008 and September 2013 that reported % of adherent 
patients. A meta-analysis was performed using a random effects model. Weights, 
odds ratios, 95% CI, and forest plots were developed for behavioral, informational, 
and combination interventions. Results: Of 29 studies screened, a total of 13 stud-
ies were eligible for inclusion in the meta-analysis. Seven studies were in patients 
with osteoporosis, 4 in ulcerative colitis, 1 in childhood-onset systemic lupus ery-
thematosus, and 1 in rheumatoid arthritis / psoriasis. Overall, patient programs 
increased adherence (OR = 2.48, 95% CI = 1.68 - 3.64, P < 0.00001) as compared 
to standard of care or no intervention. Combination interventions that used both 
informational and behavioral strategies were superior in increasing adherence (OR 
= 3.68, 95% CI = 2.20 - 6.16, P < 0.00001) compared to interventions using solely a 
behavioral strategy (OR = 1.85, 95% CI = 1.00 - 3.45, P = 0.05) or only an informational 
strategy (OR = 2.16, 95% CI = 1.36 - 3.44, P = 0.001). ConClusions: Patient programs 
and interventions can significantly improve adherence in I&I diseases as compared 
to standard of care or no intervention. Programs employing a multimodal approach 
are more effective in improving adherence than either informational or behavioral 
strategies alone. This in turn may improve patient outcomes.
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objeCtives: The American College of Chest Physicians Guideline recommends anti-
coagulant therapy for at least three months in children with venous thromboembo-
lism. The objectives of the study were to evaluate the medication utilization patterns, 
and the predictors of adherence to anticoagulant therapy in the pediatric popula-
tion. Methods: Texas Medicaid medical and prescription claims from June 01, 
2007 to September 31, 2012 were extracted for children (< 18 years) hospitalized 
for Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT). The index date was 
defined as the date of the first prescription of an anticoagulant warfarin (oral) 
and/or enoxaparin (injectable) given within 14 days after discharge from hospi-
talization. Patients hospitalized for atrial fibrillation, air/fat embolism, bleeding/
coagulation disorder within 90 days of discharge were excluded. Proportion of 
days covered (PDC≥ 80% vs. < 80%) was used to assess adherence to anticoagulants 
while controlling for demographics, cause of hospitalization, history of NSAID use, 
anticoagulant use, malignancy, drug type, and Charlson comorbidity index (CCI). A 
multivariate logistic regression analysis was used. Results: The patients (n= 57) 
had a mean (±SD) age of 14.1 (±4.9) years, were primarily female (54.4%), African 
American (61.4%), enoxaparin users (54.4%), and had a mean (±SD) CCI of 19.7 (±39.4). 
The mean (±SD) adherence rates for warfarin and enoxaparin were 85.6% (±22.3%) 
and 78.2% (±22.7%), respectively. 66.7% were adherent (PDC≥ 80%) to anticoagulant 
therapy. The median (Mean±SD) persistence with anticoagulant therapy was 84.6 
(71.9±33.3) days. Logistic regression showed that increasing age was significantly 
associated with adherence to anticoagulant therapy (Odds Ratio= 1.3, p= 0.0158), 
after controlling for covariates. ConClusions: Nearly one third of the pediatric 
patients on anticoagulant therapy after discharge from hospitalization with PE or 
DVT were non-adherent. Further research is needed to underline the factors respon-
sible for non-adherence in pediatric patients.
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480 mg respectively) before rotation the number of milligrams of each opioid was 
calculated based on equianalgesic tables using only direct medical costs, further 
a deterministic sensitivity analysis was performed. Results: The results dem-
onstrate that methadone (Amidone ®) generates average savings per patient of 
$ 84.37 to $ 5,817.00 compared to oxycodone, buprenorphine (PT), fentanyl (PT) and 
hydromorphone in the three subgroups analyzed, the sensitivity analysis shows 
that methadone remains a cost-saving option. ConClusions: Using Methadone 
(Amidone ®) is a cost-saving option for patients with acute and chronic severe pain 
secondary to cancer in Mexico, from the institutional point of view.
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objeCtives: Multiple myeloma (MM) is an incurable disease with an incidence 
of 4-7 new cases by 100.000 people. In the setting of the study, 28% of the yearly 
25 news cases of MM are candidates to autologous stem cell transplant (ASCT). 
Because of the lack of real-world economic studies, authors sought to describe 
the cost per quality-adjusted-life-year (QALY) of the MM treatment in a group of 
transplanted patients. Methods: An observational retrospective study was per-
formed and included detailed clinical data from a transplanted cohort of patients 
with MM. All patients received bortezomib based treatments. Costs were evaluated 
from the payer’s perspective and included total drug costs and hospital admission 
costs. QALYs values were obtained from the CEA Registry of Tufts University. Four 
health states were considered: complete response (CR), partial response, stability 
and progressive disease. Time between state transitions was used to calculate QALYs 
for each patient. Results: The study included 17 patients with a mean age of 61,2 
years; 12 of them (Group 1) were followed during 2,77±0,24 years and 5 (Group 2) dur-
ing 1,6±0,19 years. Global complete response rate one year after ASCT was 8/17 (47%) 
and dropped to 5/12 (41,6%) at two years. For the whole cohort the median of QALY’s 
cost was 56.198€ (IQ range 36.391-70.339). For patients with CR one year after ASCT, 
the median of QALY’s cost was 46.358€ (IQ range 36.299-67.537). For all other patients 
the median of QALY’s cost was 56.676€ (IQ range 39.114-73.613). For Group 1 patients, 
the median of QALY’s cost was 51.278€ (IQ range 36.345-73.613). ConClusions: 
These results reveal that the actual costs of MM treatment using protocols that 
include bortezomib are above the 30.000-50.000€ threshold generally admitted in 
cost-effectiveness studies.
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objeCtives: Orphan drugs (OD) require considerable expenditures, which causes 
difficulties in their market access. For several years, the price of these new therapies 
has often been criticized and considered as too high. However few studies about 
OD pricing mechanisms are available. The aim of the paper is to highlight the main 
factors that influence OD pricing in France. Methods: We collected public prices 
of 37 products designated as OD and approved by the European Medicines Agency 
until January 2014. Given that an OD can have several indications, our database 
contains 49 observations. For each observation, we calculated the ex-factory price 
without tax (defined per daily dose) defined by summary products characteristics. 
We also collected different characteristics of these products: improvement in actual 
clinical benefit (IACB), actual clinical benefit (ACB), number of OD indications, 
number of comparators drugs, number of competing orphan drugs, therapeutic 
use, target population, inclusion on the list of medicines reimbursed by National 
Health Insurance. Ordinary least squares are used to analyse the determinants of 
OD prices. Results: The distribution of OD prices is very heterogeneous, with a 
minimum of 2.34 euros and a maximum of 2882.08 euros. The average (SD) price 
is 380.675 euros (687.414). Our main results are that OD prices are significantly 
lower for OD that do not improve actual clinical benefit (-136%, p= 0.024), for OD 
with only one orphan indication (-80%, p= 0.047), and for OD with a high target 
population (-251%, p= 0.000). ConClusions: There is a need to understand OD 
pricing mechanisms. Our study shows that innovation and research efforts are 
encouraged by pricing policy.
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objeCtives: To analyze the health resource utilization (HRU) and labour absentee-
ism (LA) in Systemic Lupus Erythematosus (SLE) patients treated with belimumab 
in the Spanish clinical setting. Methods: OBSERVE is a multicenter retrospective 
medical chart-review study. Twenty-five rheumatologists from Spanish hospitals 
with > 10 SLE patients annually and > 5-years of practice experience identified adult 
SLE patients who had received 6-months of belimumab treatment. In the 6-months 
pre- and 6-months post-index periods physicians assessed: demographics, comor-
bidities, SLE disease characteristics, treatment clinical outcomes, HRU and LA data. 
Index-date is the date of the first infusion. OBSERVE primary endpoint was overall 
clinical response per physician judgment. Statistical analyses included appropri-
ate tests for paired-samples (parametric/ non-parametric). Two-way P-values 0.05 
were considered statistically significant. Results: A total of 64 patients were eli-
gible for analysis: mean age 42.7±12 years; female 89%; hypocomplementemia 70% 
and high anti-dsDNA 69%. After receiving 6-months therapy, 72%, 52% & 27% of 
